GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study

OBJECTIVE: To assess the efficacy and safety of lenzilumab in patients with severe coronavirus disease 2019 (COVID-19) pneumonia. METHODS: Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an eme...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mayo Clin Proc
Autors principals: Temesgen, Zelalem, Assi, Mariam, Shweta, F.N.U., Vergidis, Paschalis, Rizza, Stacey A., Bauer, Philippe R., Pickering, Brian W., Razonable, Raymund R., Libertin, Claudia R., Burger, Charles D., Orenstein, Robert, Vargas, Hugo E., Palraj, Raj, Dababneh, Ala S., Chappell, Gabrielle, Chappell, Dale, Ahmed, Omar, Sakemura, Reona, Durrant, Cameron, Kenderian, Saad S., Badley, Andrew D.
Format: Artigo
Idioma:Inglês
Publicat: Mayo Foundation for Medical Education and Research 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7470718/
https://ncbi.nlm.nih.gov/pubmed/33153629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mayocp.2020.08.038
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars